Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 6/20 | 0.78 |
| ▸ | NPC1 | O15118 | 5/20 | 0.78 |
| ▸ | CASP3 | P42574 | 1/20 | 0.76 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.76 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.76 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165548 | 0.86 | RAB9A (0.77) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL31661287 | 0.85 | RAB9A (0.75) | KMT2AMEN1RAB9ANPC1CASP3 | |
| SCHEMBL11887841 | 0.84 | SMN1; SMN2 (1.00) | KMT2AMEN1RAB9ANPC1CASP3 | |
| SCHEMBL6714901 | 0.84 | RAB9A (0.61) | KMT2AMEN1RAB9ANPC1CASP3 | |
| SCHEMBL29858775 | 0.84 | RAB9A (0.73) | KMT2AMEN1RAB9ANPC1CASP3 | |
| SCHEMBL20435596 | 0.84 | RAB9A (0.73) | KMT2AMEN1RAB9ANPC1CASP3 | |
| SCHEMBL3409610 | 0.84 | RAB9A (0.73) | KMT2AMEN1RAB9ANPC1CASP3 | |
| SCHEMBL11268411 | 0.83 | NPC1 (0.72) | KMT2AMEN1RAB9ANPC1CASP3 | |
| SCHEMBL13315095 | 0.83 | F10 (0.73) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3164310 | 0.82 | RAB9A (1.00) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2025-04-08 | — | — | US | disclosed |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| WO-2023061440-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-04-20 | — | — | WO | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| EP-3362436-B1 | PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS | UNIV ANTWERPEN (BE) | 2021-06-30 | — | — | EP | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1140903-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039118-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | DPM1, CYP51A1, ERG28 | KMT2A 2920/4885MEN1 142/4885RAB9A 1450/4885 |
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | C1R, CBR1, CBR3 | KMT2A 2663/4885MEN1 146/4885RAB9A 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.